Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related death worldwide with currently limited treatment options. Chronic hepatitis B virus (HBV) infection accounts for HCC development in more than 50% of cases. The lifetime risk of HBV carriers to develop cirrhosis, liver failure or HCC is estimated to be as high as 15-40%. Although several pathways and triggers contributing to HCC development have been described, many features of hepatocellular carcinogenesis and the attributed direct role of viral factors remain elusive. Host genetic factors, the geographic area and epidemiologic factors, as well as the direct risk related to chronic HBV and hepatitis C virus (HCV) infections, account for geographical and gender differences of HCC prevalence. There is growing evidence that hepatocarcinogenesis is a multistep process. Human HCC is typically preceded by chronic inflammation and apoptotic and nonapoptotic cell death with compensatory liver proliferation. However, we still lack a thorough understanding of the common underlying molecular mechanisms. High levels of HBV replication and chronicity of inflammation are known to independently increase the risk for HCC. A direct carcinogenic role of viral factors is very likely to contribute to liver cancer since HCC is known to also occur in noncirrhotic livers of individuals with an inactive chronic or even with occult HBV infection with no significant histological signs of inflammation or cytopathic effects. Furthermore, synergistic or independent viral risk factors for primary liver cancer development have been described, such as HBV genotype, integration of viral DNA into the host genome and direct effects of viral proteins. A broader understanding of these viral factors in hepatocarcinogenesis might give rise to new diagnostic and therapeutic means in the future. We review the current state of research in liver cancer development and focus on the role of direct viral factors in HBV infection.

Keywords:
Direct viral factors in hepatocarcinogenesis, Liver cancer, Hepatocellular carcinoma, Chronic hepatitis B infection, Direct role of viral proteins, Hepatocarcinogenesis
1.
El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273.e1.
2.
Jemal A, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3.
Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-3044.
4.
Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14.
5.
World Health Organisation: (2012) Hepatitis B. Fact Sheet No. 204. Geneva, WHO, 2012.
6.
Fattovich G, et al: Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008;57:84-90.
7.
Chen CJ, Yang HI: Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011;26:628-638.
8.
Yang HI, et al; Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-1143.
9.
Kim BK, Han KH, Ahn SH: Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 2011;81(suppl 1):41-49.
10.
Ott JJ, et al: Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-2219.
11.
McMahon BJ: The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 suppl):S45-S55.
12.
Asabe S, et al: The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009;83:9652-9662.
13.
Protzer U, Maini MK, Knolle PA: Living in the liver: hepatic infections. Nat Rev Immunol 2012;12:201-213.
14.
Bouchard MJ, Navas-Martin S: Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 2011;305:123-143.
15.
Brechot C: Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127:S56-S61.
16.
Mast EE, Alter MJ, Margolis HS: Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999;17:1730-1733.
17.
Ott JJ, Stevens GA, Wiersma ST: The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012;12:131.
18.
Protzer U, Schaller H: Immune escape by hepatitis B viruses. Virus Genes 2000;21:27-37.
19.
Quasdorff M, Protzer U: Control of hepatitis B virus at the level of transcription. J Viral Hepat 2010;17:527-536.
20.
Mast EE, et al: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54:1-31.
21.
Chen HL, et al: Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012;142:773-781.e2.
22.
Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 2009;373:582-592.
23.
Chu CM, et al: Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004;116:829-834.
24.
Wu TW, Lin HH, Wang LY: Chronic hepatitis B infection in adolescents who had received primary infantile vaccination. Hepatology 2013;57:37-45.
25.
Lai MW, et al: Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology 2012;143:400-407.
26.
Kim WR: Epidemiology of hepatitis B in the United States. Hepatology 2009;49(5 suppl): S28-S34.
27.
Bauer T, Sprinzl M, Protzer U: Immune control of hepatitis B virus. Dig Dis 2011;29:423-433.
28.
Lai CL, et al: Viral hepatitis B. Lancet 2003;362:2089-2094.
29.
Kennedy PT, et al: Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012;143:637-645.
30.
Lesmana CR, et al: Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia. J Dig Dis 2011;12:476-480.
31.
Chen JD, et al: Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138:1747-1754.
32.
Chu CM, Liaw YF: HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45:1187-1192.
33.
McMahon BJ: The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009;3:334-342.
34.
Hadziyannis SJ: Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011;55:183-191.
35.
Fattovich G, et al: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 suppl 1):S35-S50.
36.
Fattovich G, Bortolotti F, Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
37.
Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
38.
Bonilla Guerrero R, Roberts LR: The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol 2005;42:760-777.
39.
Bosetti C, et al: Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008;48:137-145.
40.
Chen CJ, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
41.
Iloeje UH, et al: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
42.
Lin CL, Kao JH: Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:10-17.
43.
Yu MW, et al: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-272.
44.
Tanwar S, Dusheiko G: Is there any value to hepatitis B virus genotype analysis? Curr Gastroenterol Rep 2012;14:37-46.
45.
Wai CT, et al: HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-1430.
46.
Sanchez-Tapias JM, et al: Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-1856.
47.
Jardi R, et al: Analysis of hepatitis B genotype changes in chronic hepatitis B infection: influence of antiviral therapy. J Hepatol 2008;49:695-701.
48.
Chan HL, et al: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-1498.
49.
Ringelhan M, Schmid RM, Geisler F: The NF-kappaB subunit RelA/p65 is dispensable for successful liver regeneration after partial hepatectomy in mice. PLoS One 2012;7:e46469.
50.
Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
51.
Fausto N, Campbell JS: Mouse models of hepatocellular carcinoma. Semin Liver Dis 2010;30:87-98.
52.
Summers J, Mason WS: Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004;101:638-460.
53.
Weber A, et al: Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010;51:1226-1236.
54.
Aleksic K, et al: Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology 2011;53:895-904.
55.
Vucur M, et al: Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma? Oncotarget 2010;1:373-378.
56.
Maeda S, Karin M: Oncogene at last - c-Jun promotes liver cancer in mice. Cancer Cell 2003;3:102-104.
57.
Naugler WE, et al: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-124.
58.
Maeda S, et al: IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005;121:977-990.
59.
Haybaeck J, et al: A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009;16:295-308.
60.
Pikarsky E, et al: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
61.
Luedde T, et al: Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007;11:119-132.
62.
Bettermann K, et al: TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010;17:481-496.
63.
Feng GS: Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 2012;21:150-154.
64.
Zender L, et al: Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-929.
65.
Feitelson MA: Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. Cancer Lett 2006;239:10-20.
66.
Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
67.
Zucman-Rossi J: Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010;42(suppl 3):S235-S241.
68.
Shafritz DA, et al: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981;305:1067-1073.
69.
Kremsdorf D, et al: Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006;25:3823-3833.
70.
Chemin I, Zoulim F: Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009;286:52-59.
71.
Paterlini-Brechot P, et al: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003;22:3911-3916.
72.
Shi Y, et al: Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 2012;32:231-240.
73.
Feitelson MA, Lee J: Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007;252:157-170.
74.
Hwang GY, et al: Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. J Clin Microbiol 2003;41:5598-5603.
75.
Misra KP, Mukherji A, Kumar V: The conserved amino-terminal region (amino acids 1-20) of the hepatitis B virus X protein shows a transrepression function. Virus Res 2004;105:157-165.
76.
Lucifora J, et al: Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011;55:996-1003.
77.
Bouchard MJ, Schneider RJ: The enigmatic X gene of hepatitis B virus. J Virol 2004;78:12725-12734.
78.
Kew MC: Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26(suppl 1):144-152.
79.
Madden CR, Slagle BL: Stimulation of cellular proliferation by hepatitis B virus X protein. Dis Markers 2001;17:153-157.
80.
Bouchard M, et al: Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway. J Virol 2001;75:4247-457.
81.
Elmore LW, et al: Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 1997;94:14707-1412.
82.
Su F, Schneider RJ: Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997;94:8744-8749.
83.
Jung JK, et al: Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 2007;67:5771-5778.
84.
Chan C, et al: Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein. Mol Cell Biol 2013;33:485-497.
85.
Bouchard MJ, Wang LH, Schneider RJ: Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001;294:2376-2378.
86.
Yang B, Bouchard MJ: The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol 2012;86:313-327.
87.
Zhang X, et al: Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. J Lab Clin Med 2005;145:98-104.
88.
Yokota T, et al: Telomere length variation and maintenance in hepatocarcinogenesis. Cancer 2003;98:110-118.
89.
Satyanarayana A, Rudolph KL: Telomeres and telomerase: distinctive roles in liver regeneration, cirrhosis and carcinogenesis; in Dufour JF, et al (eds): Signaling Pathways in Liver Diseases. Berlin, Springer, 2005, pp 333-339.
90.
Saini N, et al: Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int 2009;29:1162-1170.
91.
Kim CM, et al: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-320.
92.
Yu DY, et al: Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999;31:123-132.
93.
Terradillos O, et al: The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997;14:395-404.
94.
Slagle BL, et al: Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 1996;15:261-269.
95.
Lakhtakia R, et al: Hepatocellular carcinoma in a hepatitis B ‘x' transgenic mouse model: a sequential pathological evaluation. J Gastroenterol Hepatol 2003;18:80-91.
96.
Sze KM, et al: C-terminal truncated HBx is associated with metastasis and enhances invasiveness via C-Jun/ MMP10 activation in hepatocellular carcinoma. Hepatology 2013;57:131-139.
97.
Li H, et al: The mitogenic function of hepatitis B virus X protein resides within amino acids 51 to 140 and is modulated by N- and C-terminal regulatory regions. J Virol 2006;80:10554-10564.
98.
Teng J, et al: HBx-dependent activation of Twist mediates STAT3 control of epithelium-mesenchymal transition of liver cells. J Cell Biochem 2012, E-pub ahead of print.
99.
Soussan P, et al: The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003;38:343-348.
100.
Voehringer D, et al: Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 2000;165:2415-2422.
101.
Chen WN, et al: Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion. J Virol 2012;86:13533-13541.
102.
Chisari FV, et al: A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985;230:1157-1160.
103.
Na B, et al: Transgenic expression of entire hepatitis B virus in mice induces hepatocarcinogenesis independent of chronic liver injury. PLoS One 2011;6:e26240.
104.
Hildt E, et al: The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 2002;21:525-535.
105.
Su IJ, et al: Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol 2008;23:1169-1174.
106.
Wang LH, et al: Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis 2012;33:466-472.
107.
de Lope CR, et al: Management of HCC. J Hepatol, 2012;56(suppl 1):S75-S87.
108.
Yang Y, et al: The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011;137:947-952.
109.
Wang B, et al: Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol 2010;53:508-518.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.